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Abstract: Background and Objectives: Smart wearable devices are effective in diabetic foot ulcer (DFU)
prevention. However, factors determining their acceptance are poorly understood. This systematic
review aims to examine the literature on patient and provider perspectives of smart wearable devices
in DFU prevention. Materials and Methods: PubMed, Scopus, and Web of Science were systematically
searched up to October 2021. The selected articles were assessed for methodological quality using the
quality assessment tool for studies with diverse designs. Results: A total of five articles were identified
and described. The methodological quality of the studies ranged from low to moderate. Two studies
employed a quantitative study design and focused on the patient perspective, whereas three studies
included a mixed, quantitative/qualitative design and explored patient or provider (podiatrist)
perspectives. Four studies focused on an insole system and one included a smart sock device.
The quantitative studies demonstrated that devices were comfortable, well designed and useful in
preventing DFU. One mixed design study reported that patients did not intend to adopt an insole
device in its current design because of malfunctions, a lack of comfort. and alert intrusiveness, despite
the general perception that the device was a useful tool for foot risk monitoring. Two mixed design
studies found that performance expectancy was a predictor of a podiatrist’s behavioural intention to
recommend an insole device in clinical practice. Disappointing participant experiences negatively
impacted the podiatrists’ intention to adopt a smart device. The need for additional refinements of
the device was indicated by patients and providers before its use in this population. Conclusions:
The current evidence about patient and provider perspectives on smart wearable technology is
limited by scarce methodological quality and conflicting results. It is, thus, not possible to draw
definitive conclusions regarding acceptability of these devices for the prevention of DFU in people
with diabetes.
Keywords: diabetic foot prevention; smart wearable device; patient and provider perspectives
1. Introduction
Foot ulceration is the most devastating complication of diabetes, affecting up to one-
third of people with diabetes during their lifetime [1]. It has been reported that the National
Health Service in England spends over £1 billion annually managing diabetic foot ulcers
(DFUs) and their consequences, which accounts for ~10% of the National Health Service
diabetes budget [2]. Notably, these costs are higher than those spent for the treatment of
many common types of cancer [3]. Furthermore, 20% of people with a DFU may require
Medicina 2021, 57, 1359. https://doi.org/10.3390/medicina57121359 https://www.mdpi.com/journal/medicina
Medicina 2021, 57, 1359 2 of 10
lower extremity amputation because of moderate to severe infection. This complication
results in frequent and long-term hospitalisations and an increase in mortality at five years,
which may exceed 70% in some patients [4].
Crucially, a DFU is responsible for deterioration in physical function and loss of
independence in people with diabetes, resulting in psychological distress and poor quality
of life [5]. Moreover, a third of people with their first DFU suffer from clinical depression.
This condition is associated with an increased amputation and mortality risk compared
with people with no evidence of clinical depression [6].
Although most research to date has focused on psychosocial consequences of DFUs, a
growing number of studies investigate the psychological antecedents of patient engagement
in preventive foot self-care [7]. Among commonly examined psychological constructs are
patient cognitive and emotional representations of DFU risk [8–10], depression [11–13],
personality traits [14], and cognitive functioning [10,15]. The strongest evidence so far
supports the link between patient common-sense interpretation of their DFU risk and
associated emotional responses, and preventive foot self-care [7–10].
Several reports showed that psychological and behavioural factors predict the first,
but not recurrent DFUs [12,13]. A recent systematic review [16] reaffirmed these findings
indicating that psychosocial and behavioural factors play a role in the development of
first DFUs and proposed that more research is needed to determine whether these factors
influence DFU recurrence. The observation that basic foot care behavioural strategies are
ineffective for secondary DFU prevention was also supported by a randomised controlled
trial, where the intervention group reported an improved foot self-care; however, no signif-
icant differences in DFU recurrence were observed between the control and intervention
groups [17]. A subsequent study examined the role of motivational interviewing in DFU
prevention and demonstrated that people with prior DFUs reulcerate despite motivational
interviewing, as this group has biological DFU risk factors that are beyond control by
this type of intervention [18]. The observations from descriptive and interventional stud-
ies therefore necessitate a search for more effective foot selfcare behavioural strategies,
especially in secondary DFU prevention.
As we live in the era of rapidly improving medical technologies, smart wearable
devices are being developed for ongoing monitoring of DFU risk factors, with the aim
of DFU prevention through monitoring parameters, including foot pressure [19]. These
technologies are highly effective in reducing DFU recurrence through improved foot self-
monitoring [20]. Wearable devices have also been developed for monitoring wound healing
and inflammatory biomarkers (i.e., cortisol, glucose, and interleukin-6), promoting them as
a tool for managing diabetes and DFU [20].
Currently, intelligent socks and insoles are the main available wearable devices that
show promising results in the prevention of DFU [21]. In particular, smart socks—an optical
fibre-based smart textiles–allow the measurement of plantar foot temperature, whereas
insole devices monitor plantar pressure through specific sensors. Both devices may alert
patients via a mobile interface (e.g., smartphone or smartwatch) to modify their behaviour.
Recently, a proof-of-concept study conducted in the UK demonstrated that DFU recurrence
can be significantly reduced by 71% compared to the standard of care by providing timely
feedback on foot pressures to individuals through smart insoles [19].
Although promising, smart wearable devices introduce additional layers of complexity
in preventive foot self-care for people at high risk of DFU, and present challenges for
digital literacy. Currently, information about the patient and provider perspectives on
smart wearable devices and factors is limited, or facilitating their use is lacking. Several
systematic reviews that have evaluated smart technology in diabetic foot disease either
focused on the effectiveness of devices and not the patient experience [22], or evaluated
patient experience in the management of active DFUs and not DFU prevention [23,24].
Therefore, this systematic review aimed to thoroughly examine the literature on pa-
tient and provider perspectives of usability, satisfaction barriers, and facilitators concerning
the use of smart wearable devices for preventing DFU in people with diabetes.
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2. Materials and Methods
This systematic review followed the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) [25]. The PROSPERO register was searched and no prior
systematic review of our topic of interest was identified.
2.1. Search Strategy
Two reviewers (G.O. and L.V.) independently carried out the study selection, eval-
uation, and data extraction. The literature search was performed using three electronic
databases—PubMed/MEDLINE, Scopus, and Web of Science—from 22 January 1984 to
10 October 2021. An examination of the reference lists of included studies were also con-
ducted to identify other potentially relevant works. Rayyan software [26] was used to
screen and select the articles as well as exclude duplicates.
The following search terms were used: “diabetes mellitus” OR “diabetic foot” OR
“diabetic foot ulcer” OR “diabetic foot prevention” AND “digital technology” OR “smart
technology” OR “smart device” OR “smart wearable device” OR “intelligent insoles” OR
“smart insoles” OR “smart socks” OR “smart shoes”. The search terms were adapted for
use in the different databases.
2.2. Study Selection
Inclusion criteria for the selection of appropriate studies were defined as follows:
population: people with a diagnosis of type 1 or type 2 diabetes mellitus and at high
risk of developing a DFU; intervention: studies investigating the role of smart wearable
technology in DFU prevention; outcome measure: patient or provider perspectives on
usability, satisfaction, barriers, and facilitators concerning smart wearable devices; study
design: Quantitative, qualitative, or mixed studies.
Articles examining people with an active DFU, written in languages other than En-
glish, or not published in international peer-reviewed journals were excluded. Furthermore,
articles exploring nonwearable devices aimed at DFU prevention, wearable devices aimed
at monitoring active DFU, or focused on treatment of DFUs were also excluded. Commen-
taries and review articles were not considered. Disagreements between reviewers on the
eligibility of the articles were discussed, and a final decision was made based upon the
consensus of all authors.
2.3. Data Extraction and Collection Process
Two authors (G.O. and L.V.) independently read the selected articles and recorded and
extracted data using a structured proforma on Excel. This proforma included the origin
and year of publication, demographic data (sample size, sex, and age), clinical information
(type of diabetes, presence of chronic complications, and history of DFU), methodology
(study design, device type, quantitative and qualitative tools), outcomes, primary findings,
and general conclusions.
2.4. Methodological Quality Evaluation
The methodological quality of the studies included in this review was ascertained
by G.O. and L.V. The quality assessment tool for studies with diverse designs (QATSDD),
a 16-item scale appropriate for qualitative, quantitative, and mixed methodologies, was
used for this purpose. The validity and reliability of QATSDD have previously been
established [27]. A score ranging from 0 to 3 (0: not at all; 1: very slightly; 2: moderately;
and 3: complete) was given for each item. Total scores were translated into percentages
and the score for each item was reported as the mean. Any discrepancies among reviewers
were resolved through an iterative consensus approach.
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3. Results
3.1. Study Characteristics
Figure 1 shows the PRISMA flow diagram. The literature search revealed a total of
1735 articles, of which only 6 were considered eligible for inclusion. Of these, one article
was excluded after thorough examination, as it did not meet the inclusion criteria [28]. Thus,
a total of five articles were included in the analysis [29–33]. The publication year of these
studies ranged from 2017 to 2021. Three articles used a mixed quantitative/qualitative
design [31–33] and two were quantitative in nature [29,30].
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Figure 1. PRISMA flowchart illustrating the process of study selection.
The characteristics of the studies included are summarized in Table 1. Three of the five
studies (60%) were patient-related [29–31], one focused on the healthcare provider [33], and
one included both patient and provider perspectives [32]. Four articles (80%) considered
the use of smart insole devices [29,31–33] and one article focused on smart socks [30].
Four reports [29,31–33] used theory-based assessment tools to evaluate patient and
provider perceptions of usability and ease of use, whereas one study [30] employed an
in-house-designed questionnaire to examine patient levels of satisfaction with the device.
The heterogeneous nature of the study designs, aims, and key findings precluded a meta-
analysis of the data.
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Table 1. Summary of studies exploring patient and provider perspectives on the usability of smart wearable devices in













[29] Quantitative Patients DPN 17 Insoles Questionnaires
The device and smartwatch were
considered easy to use and effective by
the patients. A high level of satisfaction
was reported. More frequent pressure
alerts were associated with better
adherence, improvement in offloading,
and greater satisfaction with the device.
Reyzelman





Patients described the socks as useful,
comfortable, well-designed, and easy to
wear. The mobile application was easy
to use. Patients were highly satisfied
with the device and mobile application.
Macdonald





53 Insoles Questionnaires/focus groups
Attitude, self-efficacy, performance
expectancy, and effort expectancy were
predictors of the patients’ behavioural
intention to use an insole system.
Macdonald
et al. [33] Mixed Podiatrists - 111 Insoles
Questionnaires/
focus groups
Podiatrists considered the insole device
as a useful tool for monitoring diabetic
foot disease. Performance expectancy
was the main predictor of the intention
to use the device in clinical practice.
Providers raised several concerns about
the cost, type of footwear, and
functionality of the insole device with
elderly and remote populations.
Macdonald
et al. [32] Mixed
Patients/




expectancy, attitude, and behaviour
intention decreased significantly after 4
weeks of intervention. The patients
were particularly concerned about alert
intrusiveness and restricted choice of
footwear. Although they appreciated
the potential benefits of the smart insole,
they did not intend to adopt its current
version in the future.
Provider perspective: Patients’ negative
experiences with the insole device
negatively impacted the podiatrists’
view of the device. Although the device
was regarded as being useful for foot
monitoring, podiatrists were of the
opinion that its performance and
usability require several improvements.
Abbreviations: DFU: diabetic foot ulcer; DPN: diabetic peripheral neuropathy.
3.2. Results of the Methodological Quality Assessment
The methodological quality rating of the articles, expressed as a percentage of the
total possible score (100%), ranged from 31 to 76.2%, with a mean score of 59.6% for all
the papers. The quantitative studies obtained a lower total score compared with their
qualitative counterparts (QNT: 42.9% vs. QLT: 69.8%). These scores indicate a risk of bias
ranging from medium to high.
Table 2 shows the means of the 16 methodological criteria according to the study
design. Significant criticisms, with scores lower than 1, were reported in the quantitative
studies for the items exploring sample size, recruitment procedure, validity, and reliability
of the tools implemented and user involvement in the study design. A score of 0 was found
for user involvement in the study design. Higher scores (range: 2 to 2.25 points) were
reported for the criteria concerning the description of the aims/objectives and research
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setting, as well as the rationale for the choice of the data collection tools. The remaining
items obtained a score ranging from 1.25 to 1.75 points.
Table 2. Summary of methodological quality scores according to the study design.
Criteria







Explicit theoretical framework 1.5 3
Statement of aims/objectives in main body
of report 2.25 2.7
Clear description of research setting 2.25 1.5
Evidence of sample size considered in terms
of analysis 0.25 1.3
Representative sample of target group of a
reasonable size 0.75 1.3
Description of procedure for data collection 1.75 2.5
Rationale for choice of data collection tool(s) 2 3
Detailed recruitment data 0.75 1.3
Statistical assessment of reliability and validity
of measurement tool(s) (Quantitative only) 0.75 1.3
Fit between stated research question and method
of data collection (Quantitative only) 1.75 2.7
Fit between stated research question and format
and content of data collection tool e.g., interview
schedule (Qualitative only)
- 2.5
Fit between research question and method of
analysis (Quantitative only) 1.5 3
Good justification for analytic method selected 1.25 2
Assessment of reliability of analytic process
(Qualitative only) - 2.5
Evidence of user involvement in design 0 0
Strengths and limitations critically discussed 1.5 1.5
The scores for most of the items (11/14) were higher for the qualitative studies when
compared with the quantitative articles. The highest scores (range: 2 to 3 points) were
reported for the following criteria: theoretical framework, aims/objectives, data collection
procedure, rationale for the selected data collection tools, assessment of reliability of
analytic process, appropriateness of data collection methods, and methods of analysis used
to answer the research questions. Lower scores (approximatively 1.5 points) were noted
for the items concerning sample size, descriptions of the research setting and recruitment,
assessment of the data collection tool for reliability or validity (quantitative tools), and
the discussion of the strengths and limitations. Finally, a score of 0 was reported for user
involvement in the study design.
3.3. Patient Perspective
Three articles included a total of 62 patients with and without a history of DFUs [29,30,32],
whereas one article only defined the presence of a previous history of DFU in a cohort of
53 diabetic patients [31]. Among these, Reyzelman et al. [30] showed that patients are open
to using sock devices, as they appear safe, comfortable, well-designed, and potentially
useful in preventing DFU. They also stated that the mobile application was easy to use. A
high level of satisfaction was reported with this device. Similarly, Najafi et al. [29] revealed
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that wearing smart insoles over three months was a pleasant experience for patients and
that the device was considered easy to use and effective by the patients. Again, a high level
of satisfaction was noted for this device.
Another study examined the psychosocial factors explaining the intention of patients
to use smart insole devices [31]. It reported that self-efficacy (i.e., the belief that one could
develop the skills to use a smart insole) and attitude (i.e., positive or negative feelings
towards using the smart insole) were the strongest independent predictors of behavioural
intention. Effort expectancy (or ease of use) and performance expectancy (i.e., the belief
that smart insoles will prevent DFUs) were moderating factors. These quantitative findings
were further substantiated by a thematic analysis of a focus group discussion conducted
with people at high DFU risk. The results revealed that attitude, self-efficacy, performance
expectancy, and effort expectancy combine to predict the intention to adopt smart insole
technology.
In a subsequent study, the same group of researchers evaluated the feasibility of
podiatrist-led health coaching to facilitate smart shoe insole adoption in persons at high
DFU risk [32]. After 4 weeks of intervention, the unified theory of acceptance and use
of technology (UTAUT) questionnaire scores decreased significantly, particularly in the
performance expectancy, attitude, and behavioural intention domains. The qualitative
findings demonstrated that although participants could appreciate the potential benefits
of the smart insole, they did not intend to adopt its current version in the future. They
reported frustration when the device malfunctioned and felt that repeated alerts were
becoming intrusive during daily activities. For some participants, especially those who
had not previously experienced DFUs, the feedback appeared random and significantly
diminished their level of trust in the device. On the other hand, those with previous DFUs,
even though they believed the device was providing accurate feedback, felt that there
was little they could do to manage high pressure areas under the feet. Furthermore, they
reported that comfort was an issue because of the restrictiveness caused by the need to
wear lace-up or Velcro-enclosed footwear. Patients concluded that several improvements
were needed before the device could be used in the diabetic population.
3.4. Provider Perspectives
Together, the two studies on healthcare providers included 121 private and public
podiatrists. Macdonald et al. showed that, among the podiatrists, performance expectancy
was the single most important predictor of behavioural intention to adopt a smart insole by
a clinical practice [33]. Qualitative analyses indicated that podiatrists believed that wearable
technology would improve foot self-management. They also indicated that smart insoles
would be best for those with previous DFUs, as these people would be more motivated
to wear shoes that accommodate the device. However, concerns were raised about cost,
footwear and the device’s functionality with elderly and remote populations [33].
A more recent survey indicated that podiatrists’ attitudes towards smart insoles were
strongly influenced by their patients’ views. Disappointing participant experiences with
smart insoles negatively impacted podiatrists’ intentions to adopt the device into practice.
However, study podiatrists still saw value in real-time foot monitoring and indicated that
device refinement would increase the likelihood of future adoption [32].
4. Discussion and Conclusions
This systematic review is the first to explore patient and provider perspectives on the
acceptance of smart wearable devices in people at high risk of DFU, and to examine the
factors limiting or facilitating their use in clinical practice. We identified only a limited
number of quantitative and qualitative articles (five studies), which were at moderate-high
risk of bias, with quantitative studies rating lower on methodology scores than qualitative
studies. The main methodological issues were inadequate sample size, poorly defined
recruitment procedures, the lack of psychometric description of the assessment tools, and
in particular, the absence of user involvement in the study design. Moreover, the results of
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these studies were partially conflicting. For example, although the report by Najafi et al. [29]
demonstrated that the study participants receiving more alerts in response to elevated
plantar pressure adhered better to wearing the device and reported greater satisfaction with
the device, Macdonald et al. [32] showed diminished patient responsiveness to alerts and
general fatigue with using the device over time. Current evidence is therefore inconsistent,
and it is not possible to draw definitive conclusions about patient and provider perspectives
on the usability of these devices for the prevention of DFU. Furthermore, only one group
of researchers [31–33] has explicitly addressed psychological factors influencing patient
and podiatrist acceptance of smart wearables. There were differences among patients and
podiatrists in factors that influenced their behavioural intention to adopt a smart insole:
although attitudes towards smart technology and self-efficacy were key in activating
patients, the performance expectancy was a single most important factor motivating
podiatrists to adopt smart insoles in their clinical practice. The qualitative findings [32]
clarified, at least to some extent, the somewhat unexpected trend towards a significant
reduction in smart insole performance expectancy scores: the performance of the device
used in this study did not meet participants’ initial expectations. As a result, despite
participants’ initial adoption of the smart insole, their attitude and behavioural intention
towards future adoption were negatively impacted by their experiences.
These observations highlight an important limitation of the studies that use be-
havioural intention as a proxy for technology acceptance, thereby providing little insight
on actual technology use. Moreover, they do not account for health system complexity and
temporality, which require an approach to smart technology adoption as a dynamic and
interactive system. This necessitates that as the relationship between people at high risk
for DFU and technologies develop, technology implementation is evaluated longitudinally
so that emerging issues between people at high DFU risk and care delivery processes
can be identified and addressed. Thus, there is a need for timely patient and provider
involvement in the development and delivery of such technologies if we are to promote
sustained behaviour change. Furthermore, the theoretical models guiding such studies
are typically social cognition models and thus do not incorporate DFU-specific domains,
such as patient perceptions of their DFU risk or specific emotional responses that were
previously identified as important predictors of preventive foot self-care [7].
Thus, adequately powered research is needed to assess longitudinally whether the
patient and provider factors identified by these studies are effective in activating people at
high DFU risk and in preventing diabetic foot ulceration.
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